Available online 3 December 2023, 108565
Pexidartinib (PLX3397) is a small molecule receptor tyrosine kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) with moderate selectivity over other members of the platelet derived growth factor receptor family. It is approved for treatment of tenosynovial giant cell tumors (TGCT). CSF1R is highly expressed by microglia, which are macrophages of the central nervous system (CNS) that defend the CNS against injury and pathogens and contribute to synapse development and plasticity. Challenged by pathogens, apoptotic cells, debris, or inflammatory molecules they adopt a responsive state to propagate the inflammation and eventually return to a homeostatic state. The phenotypic switch may fail, and disease-associated microglia contribute to the pathophysiology in neurodegenerative or neuropsychiatric diseases or long-lasting detrimental brain inflammation after brain, spinal cord or nerve injury or ischemia/hemorrhage. Microglia also contribute to the growth permissive tumor microenvironment of glioblastoma (GBM). In rodents, continuous treatment for 1–2 weeks via pexidartinib food pellets leads to a depletion of microglia and subsequent repopulation from the remaining fraction, which is aided by peripheral monocytes that search empty niches for engraftment. The putative therapeutic benefit of such microglia depletion or forced renewal has been assessed in almost any rodent model of CNS disease or injury or GBM with heterogeneous outcomes, but a tendency of partial beneficial effects. So far, microglia monitoring e.g. via positron emission imaging is not standard of care for patients receiving Pexidartinib (e.g. for TGCT), so that the depletion and repopulation efficiency in humans is still largely unknown. Considering the virtuous functions of microglia, continuous depletion is likely no therapeutic option but short-lasting transient partial depletion to stimulate microglia renewal or replace microglia in genetic disease in combination with e.g. stem cell transplantation or as part of a multimodal concept in treatment of glioblastoma appears feasible. The present review provides an overview of the preclinical evidence pro and contra microglia depletion as a therapeutic approach.
Section snippetsList of abbreviationsADMEAbsorption, distribution, metabolism, and excretionADRAdriamycinAIN-76ARodent dietALSAmyotrophic lateral sclerosisALSPAdult-onset leukoencephalopathy with axonal spheroids and pigmented gliaASDAutism spectrum diseaseATPAdenosine triphosphateAUCArea under the curveBALB/cMouse lineBBBBlood brain barrierBCASBilateral common carotid artery stenosis (stroke model)C57BL/6Mouse lineCAGPromoter construct consisting of the cytomegalovirus (CMV) enhancer fused to the chicken
CSF1R structure and functionsColony stimulating factor receptor 1 (CSF1R) is a receptor tyrosine kinase belonging to the platelet-derived growth factor receptor (PDGFR) family including PDGF-α and –β, the fms-like tyrosine kinase 3 (FLT3) and the receptor for stem cell factor (c-KIT). CSF1R is expressed in myeloid cells including macrophages, monocytes, microglia and osteoclasts and is tightly regulated at the transcriptional level via a promoter upstream of exon 2 and an fms intronic regulatory element (FIRE) that works
Author contributionsMPW created Table 2&3, JS created Table 1, MKS edited Table 1, discussed and edited the manuscript, IT initiated the project, has written, edited, finalized and revised the manuscript, edited Table 2&3, and created of the figures. All authors contributed to writing or editing parts of the manuscript and agreed to submission of the final version.
FundingThe work was supported by the Deutsche Forschungsgemeinschaft (CRC1080 C02 to IT and TE 322/11-1 to IT). The funding institution had no role in data collection, analysis, preparation of the manuscript or decision to publish.
CRediT authorship contribution statementMarc-Philipp Weyer: Investigation. Jenny Strehle: Investigation. Michael K.E. Schäfer: Conceptualization, Investigation, Writing – review & editing. Irmgard Tegeder: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Uncited referencesWang et al., 2021
Wang et al., 2022
Wang et al., 2023
Wang et al., 2022
Declaration of Competing InterestThe authors declare that they have no competing financial interests or other competing interests or personal relationships that could be perceived to have influenced the work reported in this paper.
References (337)S.B. Gumusoglu et al.Maternal inflammation and neurodevelopmental programming: A review of preclinical outcomes and implications for translational psychiatryBiological Psychiatry
(2019)
R. Hadar et al.Deep brain stimulation during early adolescence prevents microglial alterations in a model of maternal immune activationBrain, Behavior, and Immunity
(2017)
M.B. Hall et al.A method for the selective depletion of microglia in the dorsal hippocampus in the juvenile rat brainJournal of Neuroscience Methods
(2022)
L.A. Hanlon et al.Depletion of microglia immediately following traumatic brain injury in the pediatric rat: Implications for cellular and behavioral pathologyExperimental Neurology
(2019)
U. Heldmann et al.Selective depletion of mac-1-expressing microglia in rat subventricular zone does not alter neurogenic response early after strokeExperimental Neurology
(2011)
T.I. Aarhus et al.Synthesis and development of highly selective Pyrrolo[2,3-d]pyrimidine CSF1R inhibitors targeting the autoinhibited formJournal of Medicinal Chemistry
(2023)
M.M. Acharya et al.Elimination of microglia improves cognitive function following cranial irradiationScientific Reports
(2016)
A. Adeluyi et al.Microglia morphology and proinflammatory signaling in the nucleus accumbens during nicotine withdrawalScience Advances
(2019)
E. Agosti et al.Glioblastoma immunotherapy: A systematic review of the present strategies and prospects for advancementsInternational Journal of Molecular Sciences
(2023)
K. Aguilar et al.Microglial response promotes neurodegeneration in the Ndufs4 KO mouse model of Leigh syndromeGlia
(2022)
B.D. Allen et al.Attenuation of neuroinflammation reverses Adriamycin-induced cognitive impairmentsActa Neuropathologica Communications
(2019)
B.D. Allen et al.Mitigation of helium irradiation-induced brain injury by microglia depletionJournal of Neuroinflammation
(2020)
M.F. Almahariq et al.Inhibition of Colony-stimulating Factor-1 receptor enhances the efficacy of radiotherapy and reduces immune suppression in glioblastomaIn Vivo
(2021)
S.R. Anderson et al.Neuronal apoptosis drives remodeling states of microglia and shifts in survival pathway dependenceElife
(2022)
J.P. Antonios et al.Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastomaNeuro-Oncology
(2017)
T. Araki et al.Microglia attenuate the kainic acid-induced death of hippocampal neurons in slice culturesNeuropsychopharmacol Rep
(2020)
M.A. Arreola et al.Microglial dyshomeostasis drives perineuronal net and synaptic loss in a CSF1R(+/−) mouse model of ALSP, which can be rescued via CSF1R inhibitorsScience Advances
(2021)
C. Barca et al.A longitudinal PET/MRI study of Colony-stimulating factor 1 receptor-mediated microglia depletion in experimental strokeJournal of Nuclear Medicine
(2022)
C. Barca et al.Short-term Colony-stimulating factor 1 receptor inhibition-induced repopulation after stroke assessed by longitudinal (18)F-DPA-714 PET imagingJournal of Nuclear Medicine
(2022)
B. Basilico et al.Microglia control glutamatergic synapses in the adult mouse hippocampusGlia
(2022)
K. Battis et al.CSF1R-mediated myeloid cell depletion prolongs lifespan but aggravates distinct motor symptoms in a model of multiple system atrophyJournal of Neuroscience
(2022)
N. Beckmann et al.Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945Acta Neuropathologica Communications
(2018)
R.E. Bennett et al.Acute reduction of microglia does not alter axonal injury in a mouse model of repetitive concussive traumatic brain injuryJournal of Neurotrauma
(2014)
R.E. Bennett et al.Partial reduction of microglia does not affect tau pathology in aged miceJournal of Neuroinflammation
(2018)
M.E. Bernis et al.Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synucleinActa Neuropathologica Communications
(2015)
K. Berve et al.Sex- and region-biased depletion of microglia/macrophages attenuates CLN1 disease in miceJournal of Neuroinflammation
(2020)
T.N. Bhatia et al.A 14-day pulse of PLX5622 modifies α-synucleinopathy in preformed fibril-infused aged mice of both sexesNeurobiology of Disease
(2023)
R.G. Biltz et al.The neuroimmunology of social-stress-induced sensitizationNature Immunology
(2022)
K.G. Blecharz-Lang et al.Minocycline attenuates microglia/macrophage phagocytic activity and inhibits SAH-induced neuronal cell death and inflammationNeurocritical Care
(2022)
A.S. Borders et al.Macrophage depletion in the murine olfactory epithelium leads to increased neuronal death and decreased neurogenesisJournal of Comparative Neurology
(2007)
M.M. Boyd et al.Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypesJournal of Neuroinflammation
(2021)
C.E. Bray et al.Chronic cortical inflammation, cognitive impairment, and immune reactivity associated with diffuse brain injury are ameliorated by forced turnover of microgliaJournal of Neuroscience
(2022)
D. Bühler et al.Protocol for the induction of subarachnoid hemorrhage in mice by perforation of the circle of Willis with an endovascular filamentTranslational Stroke Research
(2014)
O. Butovsky et al.Identification of a unique TGF-β-dependent molecular and functional signature in microgliaNature Neuroscience
(2014)
N. Butowski et al.Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An ivy Foundation early phase clinical trials consortium phase II studyNeuro-Oncology
(2016)
A.B. Campos et al.Microglial depletion has no impact on disease progression in a mouse model of Machado-Joseph diseaseCells
(2022)
N. Cartier et al.The role of microglia in human disease: Therapeutic tool or target?Acta Neuropathologica
(2014)
J.P. Chadarevian et al.Engineering an inhibitor-resistant human CSF1R variant for microglia replacementJournal of Experimental Medicine
(2023)
Z. Chen et al.The repertoire of Small-molecule PET probes for Neuroinflammation imaging: Challenges and opportunities beyond TSPOJournal of Medicinal Chemistry
(2021)
M.E. Chipman et al.Tumor progression is independent of tumor-associated macrophages in cell lineage-based mouse models of glioblastomaProceedings of the National Academy of Sciences of the United States of America
(2023)
View full text© 2023 Elsevier Inc. All rights reserved.
Comments (0)